Development of vaccines against influenza A virus (H5N1)

Chang Gung Medical Journal

Volumn 30, Issue 4, 2007, Pages 294-304

  Li, Wen Chen ^a,b   Huang, Yhu Chering ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

Influenza (H5N1); Pandemic; Reverse genetics; Vaccine

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEMBRANE ANTIGEN; RECOMBINANT VACCINE; TRIPLE VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MANUFACTURE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 34948848531     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. WHO.Cumulative numbers of confirmed human cases of avian influenza A/H5N1 reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2007_07_11/en/index.html. (accessed July 21, 2007)
2. Longini IM, Jr., Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME. Containing pandemic influenza at the source. Science 2005;309:1083-7.
3. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006;442:448-52.
4. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005;11:1515-21.
5. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192:665-72.
6. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108.
7. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72.
8. Check E. Avian flu special: is this our best shot? Nature 2005;435:404-6.
9. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005;23:2943-52.
10. Availability of H5N1 prototype strains for influenza pandemic vaccine development. http://www.who.int/csr/disease/avian_influenza/guidelines/ avian_influenza_prototype_strains/en/index.html. (Accessed Dec 31, 2006)
11. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
12. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-5.
13. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43.
14. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon MC. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-93.
15. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732-7.
16. Luytjes W, Krystal M, Enami M, Pavin JD, Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989;59:1107-13.
17. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999;73:9679-82.
18. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999;96:9345-50.
19. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000;97:6108-13.
20. Stieneke-Grober A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk HD, Garten W. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. Embo J 1992;11:2407-14.
21. Availability of H5N1 prototype strains for influenza pandemic vaccine development. http://www.who.int/csr/disease/avian_influenza/guidelines/ avian_influenza_prototype_strains/en/index.html. (Accessed Dec 31, 2006)
22. WHO.Antigenicandgenetic characteristics of H5N1 virus-es and candidate H5N1vaccineviruses developed for potential use as pre-pandemic vaccines. http://www.who.int/csr/disease/avian_influenza/guidelines/recommendationvaccine. pdf. (Accessed Dec 31, 2006)
23. Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 2005;102:16825-9.
24. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999;17:1355-8.
25. Stohr K. Pandemic influenza vaccines. http://www.who.int/csr/disease/ influenza/Klaus_Stohr_WHO.pdf. (Accessed Dec 31, 2006)
26. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51.
27. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-64.
28. Condon C. A vaccine in 50 days? Lancet 2005; 366:1686.
29. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368:991-7.
30. Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005;191:1216-20.
31. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006;194:159-67.
32. Medema JK, Meijer J, Kersten AJ, Horton R. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev Biol (Basel) 2006;123:243-50; discussion 265-6.
33. Li S, Liu C, Klimov A, Subbarao K, Perdue ML, Mo D, Ji Y, Woods L, Hietala S, Bryant M. Recombinant influenza A virus vaccines for the pathogenic human A/HongKong/97 (H5N1) viruses. J Infect Dis 1999;179:1132-8.
34. Suguitan AL, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets. PLo S Med 2006;3:e375.
35. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20:1340-53.
36. Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 2006;12:506-14.
37. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006;367:475-81.
38. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, GambottoA. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006;80:1959-64.
39. Tore H, Tang DC, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 2007;25:2886-91.
40. Hampson AW, Osterhaus AD, Pervikov Y, Kieny MP. Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. Vaccine 2006;24:4897-900.
41. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005;337:149-61.
42. Forde GM. Rapid-response vaccines - does DNA offer a solution? Nat Biotechnol 2005;23:1059-62.
43. Stephenson I, Gust I, Kieny MP, Pervikov Y. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006;6:71-2.